## 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1H-imidazo[4,5-c]pyridine
This compound is a **heterocyclic molecule** with a complex structure. It is **important for research** because it has shown **potential as a therapeutic agent** in various areas. Here's a breakdown:
**Structure:**
* **Heterocyclic:** It contains a ring structure that includes atoms other than carbon (in this case, nitrogen).
* **Imidazo[4,5-c]pyridine:** This indicates a specific arrangement of carbon and nitrogen atoms within the heterocyclic ring system.
* **Substitutions:** The molecule is further modified with:
* **Methoxy group (OCH3) at the 2-position** of the phenyl ring
* **Methylsulfinyl group (CH3SO) at the 4-position** of the phenyl ring
**Potential Applications:**
The compound's importance stems from its biological activity. Research suggests that it exhibits:
* **Anti-inflammatory properties:** Studies have shown it to inhibit certain enzymes involved in inflammation, potentially useful for treating inflammatory conditions.
* **Anti-cancer activity:** The molecule has demonstrated promising results in preclinical studies, showing it can target cancer cells and potentially inhibit their growth.
* **Neuroprotective activity:** Research is ongoing to understand its potential to protect neurons from damage, potentially beneficial for treating neurological disorders.
**Research Focus:**
Currently, the main focus of research is to:
* **Understand the exact mechanism of action:** How does this compound exert its biological effects at a molecular level?
* **Optimize its properties:** Can the structure be modified to improve its efficacy, bioavailability, or reduce side effects?
* **Evaluate its safety and toxicity:** This is crucial before human trials can be conducted.
**It's important to note that this compound is still in the research stage. While it shows promise, more research is needed before it can be used clinically.**
**For more detailed information on specific research findings, search online databases like PubMed using keywords like 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1H-imidazo[4,5-c]pyridine, imidazo[4,5-c]pyridine, or the specific activity you are interested in.**
2-(2-methoxy-4-(methylsulfinyl)phenyl)-1H-imidazo(4,5-c)pyridine: RN & structure given in first source; RN given refers to parent cpd; closely related to sulmazole [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 55690 |
| CHEMBL ID | 2110680 |
| CHEBI ID | 91691 |
| SCHEMBL ID | 145963 |
| MeSH ID | M0132482 |
| Synonym |
|---|
| 2-(4-methanesulfinyl-2-methoxy-phenyl)-3h-imidazo[4,5-c]pyridine |
| 2-(4-methanesulfinyl-2-methoxy-phenyl)-1h-imidazo[4,5-c]pyridine(isomazole) |
| 2-(4-methanesulfinyl-2-methoxy-phenyl)-1h-imidazo[4,5-c]pyridine |
| bdbm50045010 |
| BRD-A41722204-003-01-5 |
| isomazole |
| 86315-52-8 |
| 2-[2-(methyloxy)-4-(methylsulfinyl)phenyl]-3h-imidazo[4,5-c]pyridine |
| 1h-imidazo(4,5-c)pyridine, 2-(2-methoxy-4-(methylsulfinyl)phenyl)- |
| isomazole [inn] |
| isomazol [spanish] |
| isomazolum [latin] |
| 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-c)pyridine |
| isosulmazole |
| HSCI1_000150 |
| 2-(2-methoxy-4-methylsulfinylphenyl)-3h-imidazo[4,5-c]pyridine |
| 2-(2-methoxy-4-methylsulfinylphenyl)-3h-imidazo[5,4-c]pyridine |
| l8o2gv23dc , |
| isomazol |
| isomazolum |
| unii-l8o2gv23dc |
| AKOS015906082 |
| SCHEMBL145963 |
| CHEMBL2110680 |
| JQUKCPUPFALELS-UHFFFAOYSA-N |
| 2-(2-methoxy-4-methylsulfinylphenyl)imidazo[4,5-c]pyridine |
| DTXSID3020754 |
| CHEBI:91691 |
| Q27163512 |
| tert-butyl ((3r,4r)-1-benzyl-3-methylpiperidin-4-yl)(propyl)carbamate |
| 323mhb;isosulmazole |
| 86315-52-8 (free base) |
| AKOS040748596 |
| Class | Description |
|---|---|
| imidazoles | A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 58.0000 | 0.0000 | 1.1843 | 9.6140 | AID157161 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 (µMol) | 42.0000 | 0.0000 | 2.0724 | 10.0000 | AID157152 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 (µMol) | 42.0000 | 0.0003 | 1.9901 | 10.0000 | AID157152 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cellular_component | cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) |
| cytosol | cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) |
| endoplasmic reticulum | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) |
| Golgi apparatus | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) |
| cytosol | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) |
| membrane | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) |
| guanyl-nucleotide exchange factor complex | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) |
| cytosol | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) |
| membrane | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) |
| cytosol | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID60175 | The effective dose to produce a maximum increase in dP/dt diastolic blood pressure and heart rate | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID157161 | In vitro inhibition of PDE-V isolated from porcine pulmonary artery. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
| AID59591 | Maximum percentage change in dP/dt, diastolic blood pressure and heart rate produced by the compound at a dose 0.3 mg/kg | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID59301 | The effective dose to produce the 30%decrease in diastolic blood pressure. | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID157151 | Effective dose against PDE-III for increase in contractility following administration to anaesthetised dogs | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
| AID157159 | In vitro inhibition of PDE-IV isolated from guinea pig ventricle at 100 uM. | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
| AID49059 | Response ratio = (percent increase to drug)/(percent increase to 10 E-4 M isoproterenol) | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID59725 | Maximum percentage increase in heart rate produced by the compound at a dose 0.3 mg/kg | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID157152 | Inhibition of PDE 3 (phosphodiesterase III) from guinea pig ventricle | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
| AID59485 | Compound tested for contractility in anesthetized dog when administered intravenously. | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID60173 | Tested in anesthetized dog for its inotropic activity after intravenous administration | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines: the role of nitrogen position in inotropic activity. |
| AID49060 | Response ratio = (percent increase to drug)/(percent increase to 10 E-5 M isoproterenol) | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID157154 | Percent inhibition of PDE 3 (phosphodiesterase III) from guinea pig ventricle at 10 uM (or 100 uM) | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
| AID50434 | Compound tested for contractility in isolated cat papillary muscle at 10 e-4 M. | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID47761 | Inotropic activity in cat papillary muscle at 10e-5 M expressed as percent of control | 1988 | Journal of medicinal chemistry, Aug, Volume: 31, Issue:8 | Imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines: the role of nitrogen position in inotropic activity. |
| AID59622 | Percent change in heart rate in anesthetized dog | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID59124 | The effective dose was measured to produce the 10%increase in heart rate. | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID79659 | In vitro concentration required to give a 50% increase in basal contractile force in an isolated paced guinea pig papillary muscle preparation | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID59623 | Percent change in mean arterial blood pressure in anesthetized dog | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID50436 | Compound tested for contractility in isolated cat papillary muscle at 10 e-5 M. | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine. |
| AID59569 | Maximum percentage decrease in diastolic blood pressure produced by the compound at a dose 1 mg/kg | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Inotropic "A" ring substituted sulmazole and isomazole analogues. |
| AID233939 | Relative positive inotropic activity (ED50) and PDE 3 inhibition (IC50) | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||